Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients
- 1 October 2007
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 8 (5) , 282-292
- https://doi.org/10.1310/hct0805-282
Abstract
Background: The effect of adherence on the risk of virologic failure and mutations selection was verified in a prospective study. Method: At baseline, all patients had a viral load (VL) 50 copies/mL). Results: 1,133 patients completed 2,240 questionnaires/follow-up (non-nucleoside reverse transcriptase inhibitor [NNRTI] = 1,479; single protease inhibitor [PI] = 200; boosted PI = 561). Only the type of treatment and the baseline adherence rate were significantly associated with the virologic endpoint. A viral rebound rate >10% was observed in patients treated with single PI (14.7%) or boosted PI (11.7%) up to an adherence rate of 95%, whereas a similar (17.6%) rebound rate was observed only in NNRTI-treated patients with very low adherence (95% adherence rate was 6.2% in the first 6 months of therapy, lowered to 5.0% in the following 6 months, and was 3.2% thereafter. The risk of selecting for resistance-inducing viral mutation for NNRTI-treated patients was higher (4.9%) at very low adherence rates (95%). Boosted PI-treated patients showed an intermediate pattern, even if at a much lower level of risk. Conclusion: Low adherence is a major determinant of virologic failure, however different therapies have different adherence cutoffs determining a significant increment of risk. PDF Keywords adherence, HAART, HAART acceptability, NRTIs, PIs, resistance, viral mutations, virologic rebound Related articles View all related articles var addthis_config = { ui_cobrand: "Taylor & Francis Online", services_compact: "citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more", pubid: "ra-4dff56cd6bb1830b" }; var addthis_config = {"data_track_addressbar":true,"ui_click":true}; Add to shortlist Link Permalink http://dx.doi.org/10.1310/hct0805-282 Download Citation Recommend to: A friendKeywords
This publication has 18 references indexed in Scilit:
- Editorial Commentary:Adherence to Antiretroviral Therapy: How Much Is Enough?Clinical Infectious Diseases, 2006
- Visual Analog Scale of ART AdherenceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Personalised social care for adults with disabilities: a problematic concept for frontline practiceHealth & Social Care in the Community, 2006
- Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessAIDS, 2006
- Modeling the HIV Protease Inhibitor Adherence–Resistance Curve by Use of Empirically Derived EstimatesThe Journal of Infectious Diseases, 2004
- Adherence, Quality of Life, and General Satisfaction with Co-formulated Zidovudine, Lamivudine, and Abacavir on Antiretroviral-Experienced PatientsHIV Research & Clinical Practice, 2004
- High levels of adherence do not prevent accumulation of HIV drug resistance mutationsAIDS, 2003
- Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral ActivitiesAntimicrobial Agents and Chemotherapy, 2001
- Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver diseaseBritish Journal of Clinical Pharmacology, 2000
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989